In 2017, the U.S. Food and Drug Administration (FDA) approved dupilumab (which goes by the brand name Dupixent) as a treatment for atopic dermatitis (commonly known as eczema). However, recent research has identified a possible link between Dupixent and cutaneous T-cell lymphoma (CTCL), a type of cancer. If you have…
Updated: